Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-01-23
DOI
10.3389/fneur.2018.00005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
- (2017) E. Havrdova et al. EUROPEAN JOURNAL OF NEUROLOGY
- Fumarate decreases edema volume and improves functional outcome after experimental stroke
- (2017) Bettina Hjelm Clausen et al. EXPERIMENTAL NEUROLOGY
- Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients
- (2017) Qi Wu et al. JOURNAL OF IMMUNOLOGY
- Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases
- (2017) Robbert-Jan Gieselbach et al. JOURNAL OF NEUROLOGY
- Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS
- (2017) Vinzenz Fleischer et al. Multiple Sclerosis Journal
- Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
- (2017) Silvia Medina et al. Multiple Sclerosis Journal
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
- (2017) Erin E Longbrake et al. Multiple Sclerosis Journal
- Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS
- (2017) Vinzenz Fleischer et al. Multiple Sclerosis Journal
- Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
- (2017) Silvia Medina et al. Multiple Sclerosis Journal
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
- (2017) Erin E Longbrake et al. Multiple Sclerosis Journal
- Dimethyl fumarate alters B-cell memory and cytokine production in MS patients
- (2017) Matthew D. Smith et al. Annals of Clinical and Translational Neurology
- Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
- (2017) David Baker et al. EBioMedicine
- Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review
- (2016) Suneetha A. et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis
- (2016) Rui Li et al. JOURNAL OF IMMUNOLOGY
- In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity
- (2016) Dirk Luchtman et al. JOURNAL OF NEUROCHEMISTRY
- Protective effects of monomethyl fumarate at the inflamed blood–brain barrier
- (2016) Jamie L. Lim et al. MICROVASCULAR RESEARCH
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
- (2016) Klaus Lehmann-Horn et al. NEUROLOGY
- Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study
- (2016) Naila Makhani et al. PEDIATRIC NEUROLOGY
- Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation
- (2016) Catharina C. Gross et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
- (2016) Ulf Schulze-Topphoff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells
- (2016) Megan M. Blewett et al. Science Signaling
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells
- (2016) Megan M. Blewett et al. Science Signaling
- The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
- (2016) Duygu Bozkaya et al. JOURNAL OF MEDICAL ECONOMICS
- Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
- (2016) Emer Fogarty et al. Multiple Sclerosis and Related Disorders
- Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation
- (2016) Victoria A. McGuire et al. Scientific Reports
- Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
- (2015) Benedetta Parodi et al. ACTA NEUROPATHOLOGICA
- A basic overview of multiple sclerosis immunopathology
- (2015) N. Grigoriadis et al. EUROPEAN JOURNAL OF NEUROLOGY
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
- (2015) Duvyanshu Dubey et al. Expert Review of Neurotherapeutics
- Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway
- (2015) Qin Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner
- (2015) Geoffrey O. Gillard et al. JOURNAL OF NEUROIMMUNOLOGY
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
- (2015) Erin E Longbrake et al. Multiple Sclerosis Journal
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
- (2015) D. H. Miller et al. NEUROLOGY
- PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
- (2015) Dennis J. Nieuwkamp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
- (2015) Rui Li et al. Science Translational Medicine
- Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation
- (2015) Stefan Offermanns et al. TRENDS IN MOLECULAR MEDICINE
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
- (2015) Duvyanshu Dubey et al. Expert Review of Neurotherapeutics
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
- (2015) Erin E Longbrake et al. Multiple Sclerosis Journal
- The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk
- (2015) Bhupendra O. Khatri et al. Multiple Sclerosis and Related Disorders
- Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
- (2014) Verena Loleit et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Th17 cells in central nervous system autoimmunity
- (2014) Christopher Sie et al. EXPERIMENTAL NEUROLOGY
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
- (2014) Hui Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era
- (2013) J. L. Casado et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications
- (2013) Coralie Chanvillard et al. Frontiers in Immunology
- Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling
- (2012) Haiyan Peng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
- (2012) Tom A. Barr et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Anti-Inflammatory Effects of Dimethyl Fumarate in Astrocytes Involve Glutathione and Haem Oxygenase-1
- (2011) Shao Xia Lin et al. ASN Neuro
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Role of CD4+ and CD8+ T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome
- (2011) S. Gheuens et al. JOURNAL OF VIROLOGY
- Vascular Cell Adhesion Molecule-1 Expression and Signaling During Disease: Regulation by Reactive Oxygen Species and Antioxidants
- (2010) Joan M. Cook-Mills et al. ANTIOXIDANTS & REDOX SIGNALING
- Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation
- (2010) Henrik Wilms et al. Journal of Neuroinflammation
- Hepatic Overexpression of Heme Oxygenase-1 Improves Liver Allograft Survival by Expanding T Regulatory Cells
- (2010) Liang Sun et al. JOURNAL OF SURGICAL RESEARCH
- Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis
- (2010) Z. Mikulkova et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione
- (2010) Maike M. Schmidt et al. NEUROCHEMISTRY INTERNATIONAL
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- Suppression by CD4+CD25+ Regulatory T Cells Is Dependent on Expression of Heme Oxygenase-1 in Antigen-Presenting Cells
- (2008) James F. George et al. AMERICAN JOURNAL OF PATHOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started